Swiss drugmaker Roche said on Thursday its first-quarter sales rose 7% to 15.44 billion Swiss francs ($18.64 billion) and it ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax said on Wednesday the U.S. Food and Drug Administration had asked the company to produce more data on its COVID-19 ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

Novavax experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board and the ...

Just last week, the US Food and Drug Administration delayed a decision on full approval of Novavax’s Covid-19 vaccine even though it was on track to be cleared, leaving many public health ...

Full Food and Drug Administration approval would allow the vaccine to be used more widely and could offer more reassurance to people looking for options besides the existing mRNA vaccines.

The US Food and Drug Administration (FDA) has delayed the full approval of Novavax’s COVID-19 vaccine. HealthDay News — The U.S. Food and Drug Administration (FDA) has delayed the full approval of ...